Home > Expanded Access > An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Eisai Inc.

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Official Title: 
An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome
Brief Summary: 
This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
Available
EA Type
Individual Patients
Treatment IND/Protocol
Lennox Gastaut Syndrome

Drug: Rufinamide
Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).

Eligibility Criteria: 

Inclusion Criteria:

- Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.

Exclusion Criteria:

- Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 4 Years
Countries: 
Poland
Contacts: 

Eisai Medical Information
1-888-274-2378
esi_medinfo@eisai.com

Eisai Inc.
EA Number: 
Keywords: 
Central Nervous System, E2080, Rufinamide, Epilepsy, Seizures, Brain Diseases
MeSH Terms: 
Syndrome, Lennox Gastaut Syndrome, Rufinamide
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.